Contribute Try STAT+ Today

My 4-year-old daughter, Elle, is in the fight of her life. Her older sister, Milla, lost her fight last November. Their opponent? Batten disease, a rare, fast-moving, and fatal condition that destroys the central nervous system’s ability to function.

Elle has a chance to help manage, or maybe even beat, her disease that Milla didn’t have: a clinical trial in which an investigational protein is infused directly into Elle’s brain every 14 days.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I agree with Frazer Giesselmann. It’s crucial not to bog down the research in rare diseases especially if the parents are desperate because there are no other options for their children. What’s to lose?

  • Way to not mention the changes to the FDA in the past decade; orphan drug status, accelerated drug approvals, and concurrent stage studies with small cohorts to push efficacious treatments through faster. I feel for the family, but safety and efficacy has to be proven at some level.

  • Dear Frazer and Dana, That was very well written and I wish that President Trump, etc al could read this. I am so sorry about all of what you have gone through with your daughters. Love from your cousin, Nancy

  • Thank you for writing this. Our sweet six-year-old Mila was just diagnosed with Batten Disease. The connection between our two Mila/Milla is so powerful. We are devastated, but are fighting hard to start our own clinical trial as quickly as possible as none exists for her type. We are hoping that the FDA understands just what you wrote – that the process needs to be quick in order to give children with rare diseases a chance at life. So thank you for telling your story and opening up about your pain in order to help other families like ours.

  • I thought about you guys after I heard the President’s speech. I am so happy to see your article.

  • Very well written Frazier. ECS English teachers should be proud. Very moving article that brought tears to my eyes your girls are heroes and so is your entire family. We love you and pray for you all continuously. Hope someone knows how to send this to Trump. !!!!!!

  • What a heartbreaking and at the same time full of hope story. I teach genetics and one of topics I cover is rare genetic mutations and what are some of the issues with FDA approvals and the horrific cost both emotional and financial for the families. Awareness and changes in the way we fund discoveries are very much necessary. In today’s political climate I find that we are looking at a long arctic winter.

Comments are closed.